Bone fractures can be challenging to repair, particularly when injuries involve complex breaks, small bone fragments, or damage near joints. Orthopedic surgeons often use plates, screws, and other fixation devices to stabilize fractured bones while the body heals. However, some fractures are difficult to manage using traditional fixation methods alone.
Advancements in orthopedic technology are introducing new approaches to bone repair, including materials designed to bond directly to bone.
One emerging innovation is OsStic™ Technology, a synthetic bone bioadhesive being developed by Biomimetic Innovations in partnership with Sanara MedTech for the U.S. market.
Unlike conventional bone cement, which primarily provides mechanical support, OsStic is being developed to create direct adhesion between bone surfaces while providing structural support during the healing process.
Understanding how bone bioadhesion works can help healthcare professionals learn about the potential future of orthopedic fracture management.
What Is OsStic™ Technology?
OsStic is an investigational synthetic, injectable bone bioadhesive designed to support bone repair and fracture stabilization.
The technology uses a combination of phosphoserine, alpha-tricalcium phosphate (α-TCP), and calcium silicate to create a material capable of bonding with bone.
Its formulation is designed to provide adhesive properties while supporting bone remodeling over time.
OsStic is being investigated primarily for managing periarticular fractures, which occur near or involve joints.
These fractures can be particularly complicated because of the small size of bone fragments, damage to surrounding structures, and the importance of maintaining proper joint alignment.
OsStic aims to provide surgeons with an additional option for stabilizing bone fragments that may be difficult to secure using conventional methods.
The technology remains under development and is not currently cleared for commercial use in the United States.
What Is Bone BioAdhesion?
Bone bioadhesion refers to the ability of a specialized material to form an adhesive bond with bone tissue.
Traditional adhesives are commonly used to join everyday materials, but biological tissues present a very different challenge.
Bones have complex mineral structures, contain moisture, and undergo continuous biological changes.
An effective bone bioadhesive must interact with these conditions while providing appropriate mechanical properties.
Unlike ordinary glue, a bone bioadhesive intended for medical use must also meet strict biocompatibility and safety requirements.
Researchers are developing materials that can form bonds with bone in wet environments while supporting natural tissue repair.
OsStic is one example of this emerging technology.
Its formulation is designed to interact with bone at a microscopic level, forming adhesive connections that may help stabilize fractured fragments.
How Does OsStic Bone BioAdhesion Work?
OsStic uses a biomimetic approach, meaning its design draws inspiration from biological processes.
The technology combines three important components that contribute to its adhesive and structural properties.
1. Phosphoserine
Phosphoserine is a phosphorylated amino acid associated with biological mineralization processes.
It contains chemical groups capable of interacting with calcium-containing materials.
In OsStic, phosphoserine contributes to adhesive interactions between the material and bone.
These interactions are an important part of the technology’s ability to bond in moist environments.
2. Alpha-Tricalcium Phosphate
Alpha-tricalcium phosphate is a calcium phosphate material used in certain bone repair technologies.
Calcium phosphates are widely studied because their chemical composition is related to mineral components found in natural bone.
In OsStic, alpha-tricalcium phosphate contributes to the material’s mineral-based structure and setting characteristics.
3. Calcium Silicate
Calcium silicate is another component of the OsStic formulation.
It contributes to the material’s overall chemical and physical properties.
Together, these ingredients create an adhesive matrix designed to bond to bone and provide support as the material hardens.
The Bone Bonding Process
OsStic is designed to be mixed into a paste that can be injected or molded into an appropriate fracture site.
Once positioned, the material begins to harden and develop adhesive interactions with surrounding bone.
The technology is designed to form bonds with moist bone surfaces, including cortical and cancellous bone.
As the material sets, it may help hold small bone fragments in position and provide support alongside other fixation methods.
Over time, OsStic is intended to undergo remodeling as new bone develops.
These characteristics are being investigated through preclinical research and clinical evaluation.
How Is OsStic Different From Traditional Bone Cement?
Traditional bone cements and bone grafting materials serve important purposes in orthopedic surgery.
Some materials fill bone defects, while others provide mechanical support or assist with implant fixation.
However, many conventional bone cements do not form direct adhesive bonds with bone tissue.
Instead, they primarily rely on mechanical interlocking or other structural interactions.
OsStic is being developed to combine bone adhesion with structural support.
Its potential distinguishing characteristics include:
- Direct bone adhesion: Designed to bond with bone surfaces in moist conditions.
- Injectable formulation: Intended to allow placement in complex fracture areas.
- Moldable consistency: Can be shaped to accommodate irregular bone defects.
- Mechanical support: Being developed to assist fracture stabilization alongside fixation hardware.
- Bone remodeling: Intended to support gradual integration with developing bone tissue.
Preclinical mechanical testing reported by Sanara MedTech demonstrated substantially stronger bonding than conventional calcium phosphate cement under the tested conditions.
However, laboratory performance does not establish superior clinical outcomes in patients. Additional clinical evidence is necessary to determine how these properties translate into surgical practice.
Why Are Periarticular Fractures Challenging to Repair?
Periarticular fractures occur near joints such as the knee, ankle, wrist, or elbow.
These injuries can be difficult to repair because joint surfaces must be restored as accurately as possible to support proper movement and function.
Some fractures involve multiple small fragments, making traditional fixation challenging.
Surgeons may also encounter poor bone quality or areas where screws cannot achieve sufficient purchase.
These challenges can complicate fracture reduction and stabilization.
Maintaining alignment is important because irregular joint surfaces may contribute to long-term mobility problems and other complications.
Bone bioadhesive technology is being investigated as a potential way to provide additional support when conventional fixation methods face limitations.
OsStic is specifically being developed with these complex fracture situations in mind.
What Are the Potential Benefits of Bone BioAdhesive Technology?
Bone bioadhesives represent a developing area of orthopedic research.
If supported by successful clinical testing and regulatory clearance, technologies such as OsStic could provide surgeons with additional tools for managing difficult fractures.
One potential advantage is the ability to bond small fragments that are challenging to stabilize with conventional fixation hardware.
Injectable and moldable properties may also help surgeons position material within irregular bone defects.
Another area of interest is the possibility of combining adhesive stabilization with materials designed to remodel during bone healing.
These potential benefits are important research objectives, but they should not be interpreted as established improvements in surgical outcomes.
Clinical studies are needed to determine safety, effectiveness, and appropriate applications.
What Is the FDA Status of OsStic Technology?
OsStic received Breakthrough Device Designation from the U.S. Food and Drug Administration in December 2023.
The FDA Breakthrough Devices Program is intended to support the development and review of certain medical technologies that may offer significant advantages for patients with serious conditions.
However, Breakthrough Device Designation is not the same as FDA clearance or approval.
OsStic remains an investigational technology.
Sanara MedTech has previously identified the first quarter of 2027 as its anticipated U.S. commercial introduction period, subject to regulatory clearance and other development requirements.
Until applicable authorization is obtained, OsStic is not available for routine commercial use in the United States.
Sanara MedTech’s Role in Advancing Bone Repair Technology
Sanara MedTech is a medical technology company headquartered in Fort Worth, Texas, focused on surgical, wound care, and tissue repair products.
Its portfolio includes collagen-based surgical products, advanced irrigation solutions, tissue repair materials, and bone graft technologies.
Through a strategic partnership with Biomimetic Innovations, Sanara MedTech holds exclusive U.S. marketing, sales, and distribution rights for OsStic in specified applications.
This collaboration reflects Sanara’s broader focus on expanding its surgical product portfolio through research, partnerships, and innovative medical technologies.
The company’s goal is to support healthcare professionals with solutions that address important challenges in surgical care.
Learn More About OsStic™ Technology
Bone bioadhesion represents a promising area of research in orthopedic surgery.
By combining phosphoserine-based adhesion with injectable and moldable material characteristics, OsStic Technology is being developed to address some of the challenges associated with complex fracture management.
While additional clinical evaluation and regulatory clearance are required, the technology illustrates how advances in biomaterials may influence future bone repair procedures.
Sanara MedTech continues to work with innovative technology partners to expand its surgical and tissue repair portfolio.











